Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Friday October 23, 2009

DrStockPick.com Stock Report!

PSFT, VZ, PWRM, CSRH, HD, CVAT, MRK, AQNM, SGP

**************************************************************

VZ, Verizon Communications Inc.

VZ provides communication services in the United States and internationally. It operates in two segments, Wireline and Domestic Wireless.

Verizon Wireless, the nation’s largest wireless service provider, today announced a new advertising effort, “Don’t Text and Drive,” encouraging people who get into a vehicle’s driver seat to keep their hands on the wheel. Dan Mead, executive vice president and chief operating officer at Verizon Wireless, said the “Don’t Text and Drive” campaign begins next week with a mix of ads, including television, radio,

...

Recently, Schering-Plough Corporation (SGP) and Opko Health Inc. (OPK) entered into a deal which would enable Opko to acquire the assets of Schering's neurokinin-1 (NK-1) receptor antagonist program. The companies did not disclose the terms of the agreement. NK-1 receptors are mostly found in the brain.  However, they are also found in other tissues of the body. Their activation causes a release of neurotransmitters and other signaling molecules that play a key role in controlling nausea and vomiting amongst other functions.  The U.S. market for nausea and vomiting drugs is estimated to be in excess of $2 billion. Rolapitant, Schering's lead neurokinin, recently completed mid-stage studies for the prevention of nausea and vomiting due to cancer chemotherapy, surgery and other indications. The company has initiated early-stage studies for another compound in the same class.  As a result of Schering’s $41.1 billion merger agreement with ...

DrStockPick.com Stock Report!

Wednesday August 26, 2009

**************************************************************

Schering-Plough Corporation, (NYSE: SGP), today announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company’s Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age and older. The company also announced today that the EMEA has validated the MAA for nomegestrol acetate (2.5 mg) / 17 beta-estradiol (1.5mg), a combined oral contraceptive (COC) containing a unique combination of a natural estrogen identical to the estrogen produced by a woman’s own body and a selective progestin

Marathon Oil Corporation (NYSE: MRO) announced today

...

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

 

Wednesday August 5, 2009

PennyOmega.com Stock Report!

**************************************************************

Options traders made a mad dash for Chesapeake Energy Corporation (NYSE: CHK) calls on Tuesday, after the firm reported a stronger-than-expected second-quarter profit. According to data from WhatsTrading.com, the natural gas concern saw almost 33,500 calls cross the tape, more than doubling its average single-session volume of fewer than 13,900 contracts. Most popular was the August 23 call, which saw roughly 12,400 contracts change hands.

Seeger Weiss LLP announced today a $41.5 million settlement with Merck & Co., Inc. (NYSE:MRK) and Schering-Plough Corporation (NYSE:SGP) resolving nationwide fraud claims arising out of the sale and marketing of the companies’ co-ventured prescription

...

DrStockPick.com Stock Report!

Wednesday August 5, 2009

**************************************************************

Seattle-based Nordstrom, Inc. (NYSE: JWN), a leading fashion specialty retailer, announced it will open a 45,000-square-foot Nordstrom Rack, a unit of the company’s off-price retail division, in Tampa, Fla. in fall 2010. The new store will be located in the Walter’s Crossing neighborhood at the intersection of Interstate Highway 275 and the Dale Mabry Highway next to Home Depot.

NASB Financial, Inc. (NASDAQ: NASB) announced today net income for the quarter ended June 30, 2009, of $4,242,000 or $0.54 per share. This compares to net income of $4,731,000 or $0.60 per share for the quarter ended March 31, 2009, and compares to net income of $3,610,000

...

On July 15, 2009, Schering-Plough Corporation (SGP) announced that its HIV pipeline candidate, vicriviroc, has moved into the second stage of an ongoing phase II clinical study. Vicriviroc, a CCR5 receptor antagonist, is being developed for the treatment of HIV/AIDS.

In the ongoing phase II study, Schering-Plough is examining the efficacy of vicriviroc as a first-line treatment option for adult treatment-naive HIV-infected patients with R5-type virus only. The study is being conducted in two stages.

The first stage commenced in January 2008 and was conducted with 95 patients. Based on an interim analysis that was conducted following 24 weeks of treatment, the company received permission from an independent Data Safety Monitoring Board to move into the second stage of the study.

Vicriviroc is also being studied in treatment-experienced patients. Two large phase III trials (VICTOR-E3 and VICTOR-E4) in this patient population are currently ongoing.

Although the anti-HIV/AIDS market is competitive and crowded with

...

Monday March 9, 2009 Navivest

Merck & Co., Inc. (MRK) and Schering-Plough Corporation (SGP) have this morning, announced that their Boards of Directors unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine under the name Merck, in a stock and cash transaction.

Under terms of the agreement, shareholders of Schering-Plough will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough and each Merck share will automatically become a share of the combined company. Merck Chairman, President and CEO Richard T. Clark will lead the new entity.

Merck’s closing price of $22.74 on March 6, 2009, means SGP shareholders will be getting $23.61 for each of their SGP share, a 34% premium to SGP’s closing price on Friday, and values the deal at $41.1 billion.

If and when the transaction goes through, Merck shareholders will own approximately 68 percent of the combined company, with Schering-Plough

...

Highlighted stocks include Bristol Myers Squibb Co. (...

Highlighted stocks include Bristol-Myers Squibb Co. (...

Schering-Plough Corporation (SGP) is engaged in the development, manufacturing and marketing of pharmaceutical products around the world. The company focuses on prescription drugs, animal health, foot-care and sun-care products. In November 2007 Schering-Plough closed acquired Organon Bio for $15 billion.Recent prescription flight of Vytorin/Zetia prompted management to implement an aggressive cost-cutting initiative. We expect sales of Vytorin and Zetia to continue to suffer.Significant near-term risks linger, but the addition of Organon and the new cost-cutting strategy should help EPS growth. We rate the shares a Hold with a $19 price target.Jason Napodano, CFA contributed to this report.Read the full analyst report on SGP "SGP" Free Stock Analysis: Buy? Sell? Hold?Zacks Investment Research